Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain-Reference-Cited by-同舟云学术

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Published:2013-08-29 Issue:9 Volume:122 Page:1634-1648
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Soverini Simona¹,De Benedittis Caterina¹,Machova Polakova K.²,Brouckova Adela²,Horner David³,Iacono Michele⁴,Castagnetti Fausto¹,Gugliotta Gabriele¹,Palandri Francesca¹,Papayannidis Cristina¹,Iacobucci Ilaria¹,Venturi Claudia¹,Bochicchio Maria Teresa¹,Klamova Hana²,Cattina Federica⁵,Russo Domenico⁵,Bresciani Paola⁶,Binotto Gianni⁷,Giannini Barbara⁸,Kohlmann Alexander⁹,Haferlach Torsten⁹,Roller Andreas⁹,Rosti Gianantonio¹,Cavo Michele¹,Baccarani Michele¹,Martinelli Giovanni¹

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy;

2. Institute of Hematology and Blood Transfusion, Prague, Czech Republic;

3. Department of Biosciences, University of Milan, Milan, Italy;

4. Roche Applied Science, Monza, Italy;

5. Unit of Blood Diseases and Stem Cell Transplantation University of Brescia, Brescia, Italy;

6. Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico, University of Modena e Reggio Emilia, Modena, Italy;

7. Department of Clinical and Experimental Medicine, Hematology Section, Padua University School of Medicine, Padua, Italy;

8. Laboratorio Unico Area Vasta Romagna, Pievesestina di Cesena, Italy; and

9. Munich Leukemia Laboratory, Munich, Germany

Abstract

Key Points UDS demonstrated that BCR-ABL KD mutations detectable with conventional methods may just be the tip of the iceberg. The information provided by conventional Sanger sequencing may not always be sufficient to predict responsiveness to a given TKI.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/9/1634/1373432/1634.pdf

Reference45 articles.

1. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.;Cohen;Clin Cancer Res,2002

2. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.;Gorre;Science,2001

3. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.;Soverini;Blood,2011

4. Ponatinib in refractory Philadelphia chromosome-positive leukemias.;Cortes;N Engl J Med,2012

5. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.;Cortes;Blood,2012

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

2. Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort;Scientific Reports;2024-07-08

3. Resistance mutations in CML and how we approach them;Hematology;2023-12-08

4. A pilot study of implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia;Scientific Reports;2023-10-05

5. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04